Biogen hopes to bridge the gap with $7.3bn Reata buy
Biogen’s acquisition of rare neurological disease player Reata provides a much needed near-term sales lift, but at a price.
Pfizer’s oral obesity ambitions take a blow
Pfizer’s discontinuation of once-daily lotiglipron hands the advantage back to Lilly.
Car-T beyond cancer? Novartis and others say yes
Putting Car-T therapy to work in autoimmune diseases has caught the attention of several biotech and big pharma groups.